CDA Diefenbach Medpace Protocol ID ME-522-001 titled "A Phase 1 Open-label Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies After Failure of Prior Standard Therapies

Brief description of study

If you have been diagnosed with a B cell type cancer that has relapsed (come back) or is refractory (did not respond to previous treatment). The types of B cell cancers in this study include follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), or diffuse large B-cell lymphoma (DLBCL). The main goal of this study is to investigate the safety and effectiveness of an experimental drug called voruciclib as a potential treatment for different types of lymphoma.


Clinical Study Identifier: s18-00023
ClinicalTrials.gov Identifier: NCT03547115
Principal Investigator: Catherine M Diefenbach
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.